Αρχική World News FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma World News FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma Από Ogkologos - 20 Μαΐου, 2026 309 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the eNRGy study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... 17 Δεκεμβρίου, 2020 Cancer-impacted mother becomes Times Square billboard to help child come across... 21 Ιουλίου, 2023 Hiding in plain sight: How we can use immune cells to... 9 Φεβρουαρίου, 2023 Mortality Trends for Most Cancers Remain Favourable In the EU, Although... 27 Ιανουαρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS COVID-19, Vaccines, and the Immune System: Emerging Research from NCI’s SeroNet What Should People With Cancer Know About Alkaline Water? Boy Born With Heart Defect Gets Surgery To Help It Triple... EMA Recommends Granting a Marketing Authorisation for Ivosidenib